Practice patterns of post-radical prostatectomy incontinence surgery in Ontario

Christopher J.D. Wallis, MD;* Sender Herschorn, MD, FRCSC;† Ying Liu, MD;‡ Lesley K. Carr, MD, FRCSC;† Ronald T. Kodama, MD;‡ Laurence H. Klotz, MD, FRCSC;§ Refik Saskin, MD;† Robert K. Nam, MD, FRCSC*

*Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON; †Institute of Clinical Evaluative Sciences (YL, RS), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON

Published online October 22, 2014.

Abstract

Introduction: We assess the practice patterns of artificial urinary sphincter (AUS) and urethral sling insertion after radical prostatectomy (RP) from a large population-based cohort.

Methods: We examined 25,346 men in Ontario, Canada who underwent RP between 1993 and 2006. Using hospital and cancer registry data, we identified patients who subsequently underwent an incontinence procedure. We characterized the practice patterns of post-prostatectomy incontinence procedures across Ontario during the study interval.

Results: A total of 703 (2.8%) men underwent subsequent insertion of an AUS and 282 (1.1%) underwent a urethral sling procedure (985 total incontinence procedures, 3.9%) over the study period. During the study period, 121 hospitals performed RP. Among them, 32 (26%) hospitals performed both RP and AUS/sling procedures, and 89 (74%) performed RP only. Four hospitals performed AUS/sling procedures but not RP. Of the 36 institutions that performed AUS/sling procedures, the median annual case volume was 0.29 (interquartile range: 0.083-0.75). Of all incontinence procedures, 56% were performed at 3 academic institutions. When examining observed rates of AUS/sling procedures compared with expected rates from the overall cohort, 15 of 32 hospitals (47%) performed significantly fewer incontinence procedures than expected given their RP case volume (p range: <0.009–0.029) and 5 (16%) performed significantly more (p range: <0.001–0.038).

Conclusions: A small number of academic institutions provide most of the surgical care for men with incontinence following RP in Ontario. Many centres that perform RP refer out to other centres to surgically manage their patients’ incontinence.

Introduction

Clinically localized prostate cancer is commonly treated with radical prostatectomy (RP). Long-term side effects of RP include urinary incontinence and erectile dysfunction, which may decrease quality of life.1 There are many treatment options for urinary incontinence, including lifestyle modifications, biofeedback, medical and surgical therapies.2 Surgical options involve either the insertion of an artificial urinary sphincter (AUS) or urethral sling, both of which have been shown to effectively improve urinary continence.

We previously showed that the probability of undergoing surgery to treat incontinence rises with increasing time since the date of RP, reaching 4.8% at 15 years.4 Risk factors included advanced patient age at prostatectomy, radiotherapy after surgery, and surgeon volume.

To date, practice patterns of surgical management of post-prostatectomy incontinence have not been assessed at the population level. From this cohort, we examined practice patterns for post-prostatectomy continence procedures in the province of Ontario over a 14-year period.

Methods

Study population

The study subjects have previously been described by Nam and colleagues.4 Patients were drawn from a retrospective, population-based cohort of men over 18 undergoing a RP for clinically-localized prostate cancer in Ontario from January 1, 1993 to December 31, 2006. These men were identified using a surgical fee code (S651) that is specific to RP from Ontario’s single-payer model (Ontario Health Insurance Plan, OHIP). The study protocol was approved by the Sunnybrook Health Sciences Centre research ethics board.
Outcome measures

The primary outcome measure was the insertion of an AUS or urethral sling following RP. These were identified using the OHIP fee codes specific to these procedures, S559 and S548, respectively.

Exposure variables

We collected information as to which specific hospital performed both the RP and AUS or sling procedures. We linked patients from these procedures using the OHIP physician claims-database, the Canadian Institute for Health Information (CIHI) discharge database, and the Ontario Cancer Registry.

Data analysis

We descriptively characterized the annualized rates of both RP and post-prostatectomy incontinence procedure by hospital site. To evaluate the degree to which post-prostatectomy incontinence was managed at the same institution as the original prostatectomy, we then compared actual and expected frequency of incontinence procedures from each hospital site’s RP case volume. To calculate the expected frequency, we used the previously established 4.8% rate of surgical intervention. We excluded sites that had not performed at least one of each procedure from this analysis. Statistical analysis was undertaken using SAS 9.2 (SAS Institute, Cary, NC).

This study was supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred. YL and RS had access to the raw data.

Results

Of the 25,346 men who underwent a RP in Ontario during the study interval, 703 (2.8%) underwent subsequent insertion of an AUS and a further 282 (1.1%) underwent a urethral sling procedure (985 total incontinence procedures, 3.9%). The median follow-up was 6.8 years, with a mean of 7.4 years (range: 2.0-17.1).

A total of 121 different hospitals in Ontario performed RP over the study period. The distribution of these procedures was highly skewed (Fig. 1a). The median number of annual RPs performed at each site was 3.0 (interquartile range [IQR]: 0.13-17.3) with a mean of 13.49 cases (standard deviation [SD]: 25.75) per year and a maximum and minimum annual average of 200.5 and 0.67, respectively (Fig. 1a).

A total of 36 hospitals performed AUS or sling insertion, of which 32 also performed RP. Each site performed a median of 0.29 AUS/sling procedures (IQR: 0.083–0.75) and a mean of 1.45 (SD: 3.29) per year with a maximum and minimum annual average of 15.4 and 0.08, respec-
tively (Fig. 1b). For RPs and AUS/sling procedures, the top 3 hospitals performed 21.2% and 56.2% of the procedures within the province, respectively. However, the highest volume sites performing RPs were not the same as the highest volume sites performing AUS/sling procedures (Fig. 2).

Most incontinence procedures were performed at a small number of tertiary, university-affiliated institutions, with 3 sites performing 56% of all incontinence procedures. We found that only 15% of patients had their AUS or urethral sling procedure at the same hospital where they had their prostatectomy (Table 1). To further examine this practice pattern of managing post-prostatectomy incontinence, we examined the actual versus expected number of incontinence procedures performed at each hospital. We used the baseline rate of 4.8% to calculate the expected number of AUS/sling procedures based on the previous study conducted with the same cohort. Overall, of the 32 hospitals that performed both RP and AUS/sling procedures, 15 sites performed significantly fewer incontinence procedures than expected, while 5 sites performed significantly more than expected. The remaining 12 sites had insufficient samples sizes to evaluate their observed to expected ratios. When we examined the top 10 centres with the highest annual volume of RPs, 9 performed significantly fewer incontinence procedures than expected from their oncologic case volume (p range: <0.0001-0.06) (Table 2). Of all 32 hospitals, only site #3 far exceeded the expected number of AUS/sling procedures based on its RP annual volume (Table 2).

### Discussion

In this study, we characterized the management of post-prostatectomy incontinence in Ontario during 1993 to 2006 from a population-based cohort. We demonstrated that most AUS and sling insertions were performed at a small number of academic sites, and most post-prostatectomy incontinence patients were referred to centres other than where the RP was performed. One academic centre in particular received the bulk of the referrals.

There are many possible reasons for this. The most likely is that the surgeon who performed an RP may not have had expertise in performing an AUS or sling procedure. This is

---

**Table 1. Frequency of incontinence procedure (AUS/sling) and RP being performed at the same site for the 5 hospitals performing the greatest number of incontinence procedures**

<table>
<thead>
<tr>
<th>Site</th>
<th>No. AUS/slings</th>
<th>AUS/sling and RP at same site</th>
<th>AUS/Sling and RP at different sites</th>
<th>Hospital type</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>185</td>
<td>18 (9.7%)</td>
<td>167 (90.32%)</td>
<td>Academic</td>
</tr>
<tr>
<td>2</td>
<td>125</td>
<td>9 (7.2%)</td>
<td>114 (92.8%)</td>
<td>Academic</td>
</tr>
<tr>
<td>3</td>
<td>112</td>
<td>13 (11.6%)</td>
<td>99 (88%)</td>
<td>Academic</td>
</tr>
<tr>
<td>4</td>
<td>30</td>
<td>2 (6.7%)</td>
<td>28 (93%)</td>
<td>Academic</td>
</tr>
<tr>
<td>5</td>
<td>29</td>
<td>7 (24%)</td>
<td>22 (76%)</td>
<td>Community</td>
</tr>
</tbody>
</table>

AUS: artificial urinary sphincter; RP: radical prostatectomy.

---

**Table 2. Estimated and actual numbers of incontinence procedures at Ontario hospitals performing both surgeries during the study interval 1993-2006, presented for the 10 highest volume RP sites**

<table>
<thead>
<tr>
<th>Site</th>
<th>RP</th>
<th>Actual AUS/sling</th>
<th>Expected AUS/sling</th>
<th>Z-score</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3007</td>
<td>112</td>
<td>144.34</td>
<td>-2.064</td>
<td>0.0390</td>
</tr>
<tr>
<td>2</td>
<td>1827</td>
<td>1</td>
<td>87.70</td>
<td>-9.320</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>3</td>
<td>1302</td>
<td>185</td>
<td>62.50</td>
<td>8.185</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>4</td>
<td>1191</td>
<td>9</td>
<td>57.17</td>
<td>-6.010</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>5</td>
<td>890</td>
<td>7</td>
<td>42.72</td>
<td>-5.138</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>6</td>
<td>815</td>
<td>22</td>
<td>39.12</td>
<td>-2.232</td>
<td>.0256</td>
</tr>
<tr>
<td>7</td>
<td>720</td>
<td>2</td>
<td>34.56</td>
<td>-5.455</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>8</td>
<td>536</td>
<td>14</td>
<td>25.73</td>
<td>-1.896</td>
<td>.0579</td>
</tr>
<tr>
<td>9</td>
<td>466</td>
<td>9</td>
<td>22.37</td>
<td>-2.428</td>
<td>.0152</td>
</tr>
<tr>
<td>10</td>
<td>461</td>
<td>4</td>
<td>22.13</td>
<td>-3.598</td>
<td>.0003</td>
</tr>
</tbody>
</table>

AUS: artificial urinary sphincter; RP: radical prostatectomy.
potentiated by the fact that many radical prostatectomies were performed by subspecialized uro-oncologists who were in turn likely to refer their patients requiring incontinence procedures to similarly specialized colleagues in incontinence.

It is also possible that patients may not wish to have the incontinence procedure performed by the same surgeon. However, self-referral urology group practices would provide an opportunity for patients to have their post-prostatectomy incontinence provided by another surgeon within the same hospital or region. Mitchell recently showed that self-referring urology groups in private practice were significantly associated with more referrals for treating prostate cancer with radiation when these groups owned the radiation delivery machines, compared to non-self-referring urology groups. Since the procedure itself does not require tertiary-level care, there may be other factors responsible for this discrepancy.

One of these factors could be the high cost of urinary sphincters and slings to the institution. In Ontario’s publicly funded system, these are paid for by the hospital. Patients cannot pay privately for incontinence devices; therefore hospitals are obliged to cover the cost from their annual operating budget if they choose to offer the procedure. Thus, there are cost-saving incentives for both the RP surgeons and hospitals to refer out the management of post-prostatectomy incontinence. This places a financial burden on the institutions providing the bulk of the incontinence surgery. The cost of an AUS varies and is about $8500 CDN in Ontario. In the United Kingdom, the cost was about £8500 in 2010. In the United States, the cost ranged from $4500 to $21 700 between 1998-2000.

We also found that most high volume incontinence centres performed fewer RPs than average. This likely reflects both a small number of surgeons performing incontinence procedures, as well as these surgeons clustering together. We previously showed that patients who undergo RP by high-volume surgeons experience lower rates of AUS/sling procedure. Thus, patients who undergo AUS/sling surgery by surgeons performing a high volume of post-prostatectomy incontinence procedures will likely also experience better results and lower complication rates.

The established practice pattern of referrals, regardless of etiology, has likely optimized patient care by allowing a few centres (particularly site #3 in our study) to have high volumes of post-prostatectomy incontinence surgery. As mentioned above, higher volume surgeons are likely to have better outcomes. However, such geographic restriction of these procedures likely negatively affects patients’ cancer survivorship due to long wait-times for consultation and surgery, as well as geographic displacement for the surgery.

To our knowledge, no study has examined the referral patterns of AUS use for post-prostatectomy incontinence. A number of studies have examined overall practice patterns for AUS insertions, regardless of indication. Lee and colleagues found that while AUS usage has increased dramatically since its introduction, only a small proportion of all urologists in the United States (13%) were performing these procedures for any indication. Among them, only 4% performed more than 20 cases per year. Reynolds and colleagues analyzed data from American Medical Systems (AMS), the sole producer of the AUS device, and the American Urological Association. They found that there was significant geographic variability in the rate of AUS insertions on both the state and regional level, even when corrected for differences in the volume of RP and the distribution of urologists.

Matushita and colleagues further examined all cases submitted to AMS from March 1975 to December 2008 internationally, comprising 86 140 cases. They found significant regional variability both in overall numbers and trends for use; the United States accounted for 62% of all AUS procedures, with a trend towards increasing rates of use. Other regions, including Canada, France and South America, have experienced a decrease in AUS usage between 2005 and 2008. As with Lee and colleagues, they found that individual surgeon volumes of AUS procedures were very low – this corroborates our findings.

Our study has some limitations. Due to the administrative nature of the data, we could not perform chart reviews to ascertain the specific indications for AUS/sling procedures, to evaluate the extent of patient preoperative incontinence or patient response to surgery. Further, we could not determine the direct patterns of referral from surgeons and sites performing RPs to those performing AUS/sling procedures. Finally, owing to our limited sample size, we were unable to undertake subgroup analysis of the AUS and sling groups separately, owing to a lack of power. While these 2 procedures overlap, they have slightly different indications, outcomes and costs. It would be of interest to examine these differences in an updated cohort in the future.

**Conclusion**

Surgical procedures for incontinence following RP are disproportionately performed at a small number of academic sites in Ontario. Given the cost to the institution of the AUS/sling procedures in a publicly funded system, such as Canada, these sites bear an undue financial burden in managing this complication.

**Competing interests:** Dr. Wallis, Dr. Liu, Dr. Carr, Dr. Kodama, Dr. Klotz and Dr. Nam confirm that they have no relevant financial relationships. Dr. Herschorn has acted as a Consultant and as a principle investigator on scientific studies for Pfizer and Astellas.

This paper has been peer-reviewed.
References


Correspondence: Dr. Robert K. Nam, 2075 Bayview Ave., Room MG-406, Toronto, ON M4N 3M5; robert.nam@utoronto.ca